Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;11(10):e202200169.
doi: 10.1002/open.202200169.

Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives

Fatima Z Bamou  1 , Tam M Le  1 , Bizhar A Tayeb  2 , Seyyed A S Tahaei  2 , Renáta Minorics  2 , István Zupkó  2 , Zsolt Szakonyi  1
Affiliations

Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives

Fatima Z Bamou et al. ChemistryOpen. 2022 Oct.

Abstract

A series of novel heterocyclic structures, namely 1,3-oxazines, 1,3-thiazines and 2,4-diaminopyrimidines, were designed and synthesised. The bioassay tests demonstrated that, among these analogues, 2,4-diaminopyridine derivatives showed significant antiproliferative activity against different human cancer cell lines (A2780, SiHa, HeLa, MCF-7 and MDA-MB-231). Pyrimidines substituted with N2 -(p-trifluoromethyl)aniline, in particular, displayed a potent inhibitory effect on the growth of cancer cells. Structure-activity relationships were also studied from the aspects of stereochemistry on the aminodiol moiety as well as exploring the effects of substituents on the pyrimidine scaffold.

Keywords: (+)-neoisopulegol; (−)-isopulegol; 1,3-oxazines; 1,3-thiazines; 2,4-diaminopyrimidines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Preparation of (−)‐isopulegol‐based aminodiols 2 a, b and aminotriol 4.
Scheme 2
Scheme 2
Preparation of (−)‐isopulegol‐based aminodiol 6 and aminoalcohols 8 a, b.
Scheme 3
Scheme 3
Preparation of (+)‐neoisopulegol‐based aminodiols 10–12 and aminoalcohol 14.
Scheme 4
Scheme 4
Preparation of (16 a, b and oxazines 17 a–d.
Scheme 5
Scheme 5
Preparation of (−)‐isopulegol‐based pyrimidine derivatives 19–20.
Scheme 6
Scheme 6
Preparation of (−)‐isopulegol‐based pyrimidine derivatives 21–23.
Figure 1
Figure 1
Antiproliferative properties of the selected isopulegol‐based pyrimidine derivatives.
Figure 2
Figure 2
2D diagram of key binding interactions of hit (compound 20 b) with Aurora A.
See this image and copyright information in PMC

References

    1. Pruett S. T., Bushnev A., Hagedorn K., Adiga M., Haynes C. A., Sullards M. C., Liotta D. C., Merrill A. H., J. Lipid Res. 2008, 49, 1621–1639. - PMC - PubMed
    1. Aiello A., Fattorusso E., Giordano A., Menna M., Navarrete C., Muñoz E., Tetrahedron 2009, 65, 4384–4388.
    1. Vijai Kumar Reddy T., Jyotsna A., Prabhavathi Devi B. L. A., Prasad R. B. N., Poornachandra Y., Ganesh Kumar C., Eur. J. Med. Chem. 2016, 120, 86–96. - PubMed
    1. Guasch J., Giménez-Nueno I., Funes-Ardoiz I., Bernús M., Matheu M. I., Maseras F., Castillón S., Díaz Y., Chem. Eur. J. 2018, 24, 4635–4642. - PubMed
    1. Luo L., Yamamoto H., Org. Biomol. Chem. 2015, 13, 10466–10470. - PMC - PubMed

Publication types